title: Proinflammatory cytokine gene expression in whole blood from patients undergoing coronary artery bypass surgery and its modulation by pentoxifylline.
abstract: The influence of coronary artery bypass grafting (CABG) on spontaneous and lipopolysaccharide (LPS)-stimulated release of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, and IL-10 as well as its modulation by pentoxifylline (PTF) were studied in a prospective, randomized, double-blinded study. 12 patients undergoing elective CABG were randomly assigned to receive either saline or PTF (1 mg/kg as a loading dose followed by 1 mg/kg/h) intraoperatively. Blood samples were obtained (A) preoperatively, (B) 20 min after CABG, and (C) 24 h after CABG. Cytokine plasma levels as well as LPS-stimulated cytokine secretion were measured in a whole blood culture system ex vivo and correlated with mRNA expression in peripheral blood mononuclear cells. In addition, the dose-response characteristics of modulation of the cytokine response by PTF were studied in cultured whole blood in vitro. Plasma IL-6 and IL-10-levels were significantly elevated after CABG, whereas neither TNF-alpha nor IL-1beta were detectable. In contrast to the spontaneous release of IL-6 and IL-10, the expression of all cytokines studied was significantly reduced upon ex vivo LPS stimulation early after CABG. Proinflammatory cytokine response upon LPS stimulation was restored 24 h after CABG for the group mean, however, with substantial interindividual heterogeneity. Therapeutic doses of PTF in vitro attenuated LPS-induced TNF-alpha (-50.5%) and most notably IL-10 (-83.9%) release, whereas IL-1beta was even increased (+45.7%). However, application of PTF during CABG neither inhibited the spontaneous production of IL-10 nor modulated cytokine production ex vivo. These results suggest a biphasic response of stimulated peripheral blood mononuclear cell cytokine gene expression during CABG with an initial tolerance to LPS stimulation. The application of PTF during CABG in doses that are primarily based on its use in occlusive arterial disease do not seem to modulate the release of the cytokines studied.
authors.affiliation: Klinik für Anästhesiologie und Intensivmedizin, Universität des Saarlandes, Homburg/Saar, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Kleinschmidt
authors.forename: G A
authors.initials: GA
authors.lastname: Wanner
authors.forename: D
authors.initials: D
authors.lastname: Bussmann
authors.forename: J P
authors.initials: JP
authors.lastname: Kremer
authors.forename: T
authors.initials: T
authors.lastname: Ziegenfuss
authors.forename: M D
authors.initials: MD
authors.lastname: Menger
authors.forename: M
authors.initials: M
authors.lastname: Bauer
mesh_terms: D000328:Adult; D000368:Aged; D001699:Biometry; D001026:Coronary Artery Bypass; D016207:Cytokines / Q000097:blood / Q000235:genetics*; D004311:Double-Blind Method; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000494:pharmacology*; D011446:Prospective Studies; D013268:Stimulation, Chemical
chemical_list: D016207:Cytokines; D008070:Lipopolysaccharides; D010431:Pentoxifylline